Tenofovir alafenamide (TAF) is a prodrug of tenofovir with improved liver and plasma stability compared to TDF.It delivers higher active drug intracellularly with lower systemic tenofovir exposure, resulting in better renal and bone safety profiles.
Approved Indications
Chronic hepatitis B virus (HBV) infection in adults
HIV‑1 infection in combination with other antiretrovirals
Key Features
Improved renal & bone safety vs tenofovir disoproxil fumarate (TDF)
High antiviral potency
Once‑daily oral dosing
Low drug‑drug interaction potential
Preferred tenofovir form in modern HBV/HIV regimens
Applications
API, intermediates, reference standards for R&D, generic registration and commercial production.
ECROBOT CO., Ltd, Business Registration Number : 220-88-71747, CEO J.W.Park, TEL : +82-2-552-7676, E-mail : E-mail : Contact us Address : (Hwanghwa B/D 11F, Yeoksam-dong)320, Gangnam-daero, Gangnam-gu, Seoul, South Korea
China [CN] 
Click enlarge Image